Tex. Health & Safety Code § 491.001 · Subchapter A. GENERAL PROVISIONS
DEFINITIONS.
Text — Current through the 89th 2nd Called Legislative Session, 2025
In this chapter:
(1) "Individualized investigational treatment" means a drug, biological product, or device unique to and produced exclusively for use by a patient, based on the patient's genetic profile. The term includes individualized gene therapy antisense oligonucleotides and individualized neoantigen vaccines.
(2) "Life-threatening illness" means a disease or condition with:
(A) a significantly increased likelihood of death unless the course of the disease or condition is interrupted; or
(B) potentially fatal outcomes and for which the goal of clinical trials is survival.
(3) "Severely debilitating illness" means a disease or condition that causes major irreversible morbidity.
Notes and commentary — not statutory text
History
Added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1, eff. September 1, 2025.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.491.V3.htm
- Text hash
- sha256 c5883dd76878b09f41a8fa440baefc74116c03df67e32407ff00ef5d217b1f03
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
- the Legislature enacted more than one unit numbered 491.001; this is the one the Council prints in hs.491.v3.htm
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.